Carvedilol Tablets 25 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Carvedilol Tablets 25 mg | Manufacturer
Product image for Carvedilol Tablets 25 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Carvedilol |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | IP / BP |
| Product Type | Tablet |
| Category | Antihypertensive drugs – Beta Blocker |
| Subcategory | Beta Blocker |
| Active Ingredient | Carvedilol |
| Strength | 25 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Antihypertensive drugs – Beta Blocker |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Carvedilol Tablets 25 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. First-line management of mild, moderate, and severe essential hypertension. 2. Adjunctive treatment in chronic stable angina pectoris and reduction of cardiovascular mortality. | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Carvedilol Tablets 25 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Carvedilol Tablets 25 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Carvedilol Tablets 25 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Carvedilol Tablets 25 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally once or twice daily at the same time each day, with or without food. Do not discontinue abruptly; gradual downward titration is recommended under medical supervision. | ||||||||||||||||||||||||
| Side Effects | Common: Peripheral edema (ankle swelling), dizziness, headache, flushing, fatigue. Uncommon: Postural hypotension, palpitations, dyspepsia, dry cough, muscle cramps. Rare: Bradycardia, severe hypotension, syncope, hyperkalemia, angioedema. | ||||||||||||||||||||||||
| Warnings and Precautions | Hypotension Monitoring: Monitor seated blood pressure during initial titration. Electrolyte Balance: Periodically verify serum potassium and renal clearance in patients with underlying renal insufficiency. Heart Failure Caution: Use with careful clinical assessment in heart failure patients. | ||||||||||||||||||||||||
| Contraindications | 1. Hypersensitivity to Carvedilol or related cardiovascular agent classes. 2. Severe cardiogenic shock, second- or third-degree atrioventricular block without a pacemaker. 3. Clinically severe hypotension (systolic BP < 90 mmHg). 4. Pregnancy and lactation (for ACE inhibitors and ARBs). | ||||||||||||||||||||||||
| Drug Interactions | 1. Other Antihypertensives & Diuretics: Additive blood-pressure-lowering effects requiring monitored dose titration. 2. Potassium Supplements & Potassium-Sparing Diuretics: Elevated risk of hyperkalemia (with RAAS blockers). 3. NSAIDs: May diminish antihypertensive response and increase risk of acute renal dysfunction. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Carvedilol Tablets 25 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Carvedilol Tablets 25 mg? | The source specification is IP / BP; confirm the required standard before contracting. |
| What quality tests are applicable for Carvedilol Tablets 25 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Carvedilol Tablets 25 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Carvedilol Tablets 25 mg? | Provide forecast volume, target market, strength and packaging requirements. |
Related Products
✚
Carvedilol Tablets 12.5 mg ExporterView product →
✚
Carvedilol Tablets 12.5 mg ManufacturerView product →
✚
Carvedilol Tablets 12.5 mg SupplierView product →
✚
Carvedilol Tablets 25 mg ExporterView product →
✚
Carvedilol Tablets 25 mg SupplierView product →
✚
Carvedilol Tablets 3.125 mg ExporterView product →
✚
Carvedilol Tablets 3.125 mg ManufacturerView product →
✚
Carvedilol Tablets 3.125 mg SupplierView product →
✚
Carvedilol Tablets 6.25 mg ExporterView product →
✚
Carvedilol Tablets 6.25 mg ManufacturerView product →
✚
Carvedilol Tablets 6.25 mg SupplierView product →
✚
Atenolol Tablets BP 100 mg ExporterView product →
